Nevertheless, available biomarker data demonstrated more AD-like profiles (lower CSF amyloid and higher tau) for APOE4 carriers and CI participants, supporting the interpretation that these individuals were more likely to be in preclinical AD stages. Here, APOE is linked to Alzheimer disease.